211results about How to "Inhibit expression" patented technology

The invention relates to the technical field of microorganisms, in particular to a viable bacterium preparation of a lactobacillus paracasei strain as well as a preparation method and application of the viable bacterium preparation. The viable bacterium preparation comprises a lactobacillus paracasei strain and auxiliary materials, and the preservation number of the lactobacillus paracasei strain is CGMCC (China General Microbiological Culture Collection Center) No.27974. The viable bacterium preparation can inhibit the growth of streptococcus mutans, reduce the formation of a dental plaque biofilm caused by the streptococcus mutans, reduce the content of a mature dental plaque biofilm, inhibit the level of water-insoluble exopolysaccharides generated by the streptococcus mutans, reduce the expression quantity of cariogenic genes gtfB, gtfC, gtfD, ftf and LuxS of the streptococcus mutans, improve the cariogenic activity of the streptococcus mutans and improve the cariogenic activity of the streptococcus mutans. The adhesion rate of streptococcus mutans on a hydroxyapatite tooth model is reduced, and a beneficial in-vitro probiotic function is achieved.

The invention relates to an anti-aging oligopeptide for beauty and skin care, the oligopeptide has an amino acid sequence as shown in (X1) (R or K or H) G (D or E) # (X2), X1 represents one amino acid of G, A, V, L, I and P or represents that no amino acid exists, # represents one amino acid selected from A, V, D, E, N and Q, and X2 represents G and P or represents that no amino acid exists. The oligopeptide is a functional fragment of XVII type collagen, can induce in-vivo collagen synthesis or simulate a protein regulation function, has the effects of promoting cell self-cleaning, helping to remove aged skin cells, reconstructing skin rhythm, maintaining a good skin structure, resisting initial aging, promoting skin repair and regeneration, reducing fine wrinkles and the like, and is mild in action, free of side effects and free of toxic and side effects. The product has no obvious adverse reaction on human body, and is a good beautifying and anti-aging product.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The invention belongs to the field of biological medicines, and particularly relates to a modified double-stranded oligonucleotide, and a conjugate and a composition thereof. The double-stranded oligonucleotide provided by the invention effectively enhances the activity of the double-stranded oligonucleotide for inhibiting the expression of the target gene by performing specific modification on the nucleotide at a specific site, can efficiently inhibit the expression of the target gene in both in-vitro and in-vivo experiments, and surprisingly, the double-stranded oligonucleotide provided by the invention has a good application prospect. The modification on the double-stranded oligonucleotide can be generally used for siRNA designed for various different target genes, and the inhibition rate of the siRNA on the target genes can be effectively improved.

The invention belongs to the technical field of biology, and particularly discloses application of moxidectin in preparation of a medicine for preventing and treating rotavirus. Compared with the prior art, the invention discovers that the moxidectin can significantly inhibit RV replication, and discovers that the moxidectin not only inhibits transcriptional level expression of VP6 protein of rotavirus, but also can reduce the expression level of the VP6 protein. Therefore, moxidectin can be used for preventing or treating rotavirus.

The invention discloses paenibacillus kribbensis exopolysaccharide and application thereof in prevention and control of iridovirus diseases of micropterus salmoides. The invention provides a paenibacillus kribbensis exopolysaccharide. The paenibacillus kribbensis exopolysaccharide is prepared from a fermentation product of a paenibacillus kribbensis space mutation delta PS04-17 strain. As a fish feed additive, the paenibacillus kribbensis exopolysaccharide has better in-vivo safety, has a promoting effect on the growth of the largemouth bass, and can promote the growth and weight gain of the largemouth bass and reduce the feed coefficient of the largemouth bass. Meanwhile, as a drug for resisting LMBV virus infection, the compound can inhibit expression of viruses in target tissues, alleviate virus-induced fish body target tissue structure damage and reduce the death rate caused by virus infection. Besides, the paenibacillus kribbensis exopolysaccharide serving as a disease-resistant immunopotentiator can maintain intestinal health of the micropterus salmoides, is simple to prepare, low in cost and easy to obtain in quantity, and provides more products and methods for prevention and control of the iridovirus disease of the micropterus salmoides.

The invention provides an application of a recombinant XVII type humanized collagen or a composition containing the recombinant XVII type humanized collagen in preparation of a preparation for preventing and / or treating lupus erythematosus, which can overcome the defect that more adverse reactions are generated in treatment in the existing scheme.

The invention discloses an application of pinoresin-4-O-glucoside in preparation of a medicine for treating allergic asthma diseases, and according to the application provided by the invention, the pinoresin-4-O-glucoside can inhibit expression and activity of induced nitric oxide synthase, remarkably improve airway hyperresponsiveness, relieve lung inflammation and relieve expression of asthma related indexes, and can be used for treating allergic asthma diseases. The application has a prospect of developing a novel anti-asthma medicine.

The invention relates to siRNA for treating androgenetic alopecia, a nano preparation and a preparation method of the siRNA. The siRNA comprises a positive-sense strand and an antisense strand, the positive-sense strand is as shown in SEQ ID NO. 1, and the antisense strand is as shown in SEQ ID NO. 2. The siRNA disclosed by the invention can be used for efficiently and quickly inhibiting the expression of an androgen receptor in vivo and in vitro. When the medicine containing the siRNA is applied to the surface of the alopecia skin, the treatment effect can be quickly achieved, the hair growth speed is increased, and the hair regeneration time of the alopecia part is shorter.

The invention belongs to the technical field of gene engineering, and provides a gene OsMYB1 and application thereof in negative regulation of anthocyanin synthesis. The cDNA (complementary deoxyribonucleic acid) sequence of the gene OsMYB1 is as shown in SEQ ID NO. 1. A systematic molecular biology experiment proves that the OsMYB1 inhibits the expression of the OsDFR by combining with a promoter region of an anthocyanin synthesis key structural gene OsDFR, so that the synthesis of anthocyanin is inhibited. Meanwhile, the OsMYB1 can form an MBW ternary complex with the OsB2 and the OsPAC1 to competitively inhibit the synthesis of the anthocyanin, which indicates that the transcription factor OsMYB1 is a negative regulation factor for the synthesis of the rice anthocyanin, the content of the rice anthocyanin can be increased by knocking out the transcription factor OsMYB1, and a certain theoretical basis is provided for cultivating high-quality purple rice with high anthocyanin content.

The invention relates to the technical field of biological medicines, in particular to a nano-drug for treating idiopathic pulmonary fibrosis as well as a preparation method and application of the nano-drug. The nano-particles are prepared by loading the TGF-beta1 inhibitor and the RSV by using hemoglobin, so that the TGF-beta1 inhibitor and the RSV are cooperated to effectively treat idiopathic pulmonary fibrosis.

The invention discloses a medicine for treating tumors containing TP53 gene mutation. The medicine comprises a thymine DNA (Deoxyribose Nucleic Acid) glycosylase (TDG for short) inhibitor and pharmaceutically acceptable auxiliary components of the thymine DNA glycosylase (TDG for short) inhibitor. The TDG inhibitor used in the invention can effectively inhibit human TDG protein expression, and has a good treatment effect on TP53 gene mutation-containing tumors.

The invention provides a uric acid reducing composition containing fructus gardeniae and a preparation method of the uric acid reducing composition, and belongs to the technical field of medicines. The preparation method comprises the following steps: fermenting mulberry leaves, chicory, cape jasmine and kudzu vine roots through lactobacillus rhamnosus and bifidobacterium longum, separating probiotics from fermentation liquor, adding immobilized ionic liquid into the fermentation liquor, introducing carbon dioxide for adsorption, filtering, adding solids into ethanol, heating for desorption, concentrating to obtain an extract 1, precipitating filtrate with ethanol to obtain an extract 2, and carrying out freeze-drying to obtain the folium mori-chicory-cape jasmine extract. The preparation method comprises the following steps: embedding probiotics together with sodium alginate to prepare a uric acid-reducing embedding material, and uniformly mixing the uric acid-reducing embedding material with the extract 1, vitamin C and tea polyphenol to prepare the uric acid-reducing composition containing fructus gardeniae. The prepared uric acid reducing composition containing fructus gardeniae can promote uric acid excretion, inhibit sodium urate crystallization, improve the antioxidant effect, repair intestinal barriers, relieve inflammation, inhibit xanthine oxidase (XOD) activity and expression and reduce the blood uric acid level, has a good uric acid reducing effect and has a wide application prospect.

The invention discloses a method for killing brain tumor cells in vitro. According to the embodiment of the invention, the method comprises the following step: carrying out contact treatment on ABBV-075 and separated brain tumor cells so as to kill the brain tumor cells. According to the method provided by the embodiment of the invention, the efficiency of killing the brain tumor cells in vitro can be improved.

The invention discloses siRNA (small interfering Ribonucleic Acid) nanoparticles capable of efficiently targeting mononuclear phagocytes and mediated by intercellular effect of neutrophils as well as a preparation method and application of the siRNA nanoparticles. The siRNA nanoparticles comprise mesoporous silica nanoparticles carrying siRNA, and functional cell membranes over-expressing ICAM-1 ligands are wrapped outside the mesoporous silica nanoparticles carrying siRNA. Key sentinel cells (mononuclear phagocytes, MPs) for targeted mitochondrial DNA release to treat inflammatory responses caused by mtDNA. The efficient delivery of MPs is realized by using a functionalized cell membrane of an overexpressed ICAM-1 ligand to wrap nano-particles and by virtue of infiltration and rapid apoptosis of a large number of neutrophils in an inflammatory microenvironment and a process (cell burial effect) of specific phagocytosis of the neutrophils by the MPs. Compared with a traditional targeting scheme, the in-vitro targeting efficiency and the in-vivo targeting efficiency of the FCM-coated siNPs scheme are improved by 360% and 120% respectively. The siRNA is guided to target MPs, and the expression of STING is inhibited, so that the inflammatory reaction caused by mtDNA release is regulated and controlled, and an excellent anti-inflammatory curative effect is shown in an inflammatory model mouse.

The invention relates to application of a UHRF1 inhibitor in preparation of a medicine for treating tissue fibrosis after spinal cord injury, and belongs to the technical field of biological medicine. The invention proves that the expression of UHRF1 can be increased due to spinal cord injury; compared with mice of a false operation group, the mice of which the UHRF1 is specifically knocked down in the fibroblasts have the advantages that fibrosis caused by spinal cord injury is obviously reduced, nerve regeneration is promoted, and the motor function is obviously improved. In the aspect of mechanism, the knock-down of UHRF1 leads to the reduction of the number of proteins combined on a PPM1A gene promoter, the weakening of the transcription inhibition effect and the promotion of the expression of the PPM1A gene, while the PPM1A can inhibit the phosphorylation of Smad2 / 3 and inhibit the conduction of a TGF-beta1 / Smads pathway, thereby inhibiting tissue fibrosis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of elcaindopristat in preparation of an anti-sepsis product. According to the application disclosed by the invention, a sepsis mouse model is constructed through cecal ligation-puncture (CLP), and the medicine is administered by taking the elcaindopristat as an active component, so that the fatality rate of the sepsis mouse can be remarkably reduced, the survival rate of the sepsis mouse can be increased, the content of inflammatory factors in serum of the mouse can be reduced, the abnormality of tryptophan-kynurenine metabolites can be improved, and the curative effect of the sepsis mouse can be improved. And morphological abnormalities of lung and intestinal tissues. The icaindopristat is suitable for comprehensive prevention and treatment of sepsis, and has clinical popularization and application potential.

The invention discloses application of caffeic acid phenethyl ester to improvement of negative effects of high-carbohydrate feed on fish growth and metabolism, and belongs to the technical field of aquaculture. The caffeic acid phenethyl ester is added into a high-carbohydrate feed formula, so that the metabolic capability of adipose tissues, livers and muscles of the grass carp and the weever on glucose can be remarkably enhanced, ectopic deposition of lipid in the livers and the muscles is relieved, fatty liver diseases are improved, muscle protein deposition is promoted, and the immunity of the grass carp and the weever is improved. The inhibiting effect of the high-carbohydrate feed on the growth performance of the grass carp and the weever is reversed. The invention further provides formulas of the high-carbohydrate feed containing the caffeic acid phenethyl ester for the grass carp and the weever respectively, and data support is provided for research on improvement of the utilization capacity of the grass carp and the weever on the high-carbohydrate feed.

The invention relates to the field of biological medicine, in particular to an Mmrn1 targeted inhibitor, an inhibition method and application. According to the application disclosed by the invention, firstly, the relationship between the expression of the MMRN1 gene in the acute myelogenous leukemia (AML) and the regulation and control of a'siglecan-siglecc 'axis is creatively disclosed. Therefore, the invention firstly provides a small interfering RNA (Ribonucleic Acid) targeting the Mmrn1 in the leukemia stem cell, and an application of the small interfering RNA in preparation of a'sialic acid glycan-siglecc 'axis immune checkpoint inhibitor.

A method for treating a disease associated with cell autophagy functional deficiency and / or lysosomal functional deficiency, such as neurodegenerative diseases, by inhibiting KEAP1 activity and / or enhancing the expression of nuclear erythroid 2-related factor 2 (NRF2) and / or the downstream genes thereof. The expression of NRF2 and / or the downstream genes thereof is enhanced with a KEAP1 inhibitor, a KEAP1 gene knockdown, and / or an NRF2 activator. The method and product can increase the acidic environment in the lysosomes of neurons, increase the enzymatic activity of cathepsins, decrease the abnormal storage of proteins, protect mitochondrial homeostasis in neurons, and increase the capability of mitochondria to generate ATP.

The application discloses a sensitized ferroptosis lipid nano regulator and a preparation method and application thereof, and belongs to the technical field of new adjuvants and new dosage forms of drug preparation combined treatment. The lipid nano regulator is co-assembled by a GPX4 inhibitor and a FASN inhibitor through intermolecular forces, and is modified with an oxidation-reduction sensitive PEG modifier, a molar ratio of the GPX4 inhibitor and the FASN inhibitor is 10:1-1:10, a mass ratio of the sum of the GPX4 inhibitor and the FASN inhibitor to the PEG modifier is 10:90-90:10, and the intermolecular forces include pi-pi stacking force, hydrophobic force and hydrogen bond. The co-assembled nano preparation provides a new strategy and more choices for the development of drug delivery, and meets the urgent needs of high-efficiency and diverse ferroptosis treatment strategies in preparations in the clinic.

The invention relates to application of amlexanox and polydatin in preparation of a preparation for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of medicines. The invention provides application of amlexanox combined with polydatin in preparation of a medicine for preventing and / or treating radiation-induced lung injury. The amlexanox and the polydatin are combined for use, so that the radiation-induced lung injury caused by ionizing radiation can be well prevented and / or treated, and the survival rate of a radiation-induced lung injury model mouse is increased by more than 50% on the premise of remarkably reducing the administration dosage of the amlexanox and the polydatin; the traditional Chinese medicine composition has the characteristics of small dosage, excellent prevention and / or treatment effect, no toxic or side effect and no dose dependence.

The invention relates to the field of biological medicine, in particular to a shRNA (short hairpin Ribonucleic Acid) inhibitor expressed by Engrailed-1 protein, an RNAi (Ribonucleic Acid Interfere) exosome as well as a preparation method and application of the RNAi exosome. According to the shRNA inhibitor expressed by the Engraled-1 protein, a nucleotide sequence as shown in SEQ ID NO.1 is selected as a target sequence, the shRNA designed according to the target sequence is high in specificity, and expression of the Engraled-1 protein can be remarkably inhibited. Meanwhile, through the shRNA inhibitor provided by the invention, the RNAi technology is utilized, and the amniotic stem cell exosome is used as a carrier, so that the Engrailed-1 protein can be accurately and remarkably inhibited, the problems of poor curative effect and high cost of a traditional scar repair technology are avoided, and scar formation caused by the Engrailed-1 protein is expected to be relieved or cured.

The present invention relates to a composition for preventing, improving, or treating degenerative arthritis comprising a steamed ginger extract or 1-dehydro-6-gingerdione isolated therefrom as an active ingredient. The steamed ginger extract according to the present invention or 1-dehydro-6-gingerdione isolated therefrom exhibits an effect of inhibiting inflammatory cytokine expression, cartilage tissue recovery, cartilage production, or cartilage degradation, and inhibits the expression of I-xB or NF-κB protein involved in inflammatory cytokine and MMP production, and thus is expected to be effectively used in functional food compositions, pharmaceutical compositions, or the like for preventing, improving, or treating degenerative arthritis.

The invention discloses application of mycobacterium protein in preparation of an antigen presentation inhibitor. The amino acid sequence of the mycobacterium protein is as shown in SEQ ID NO: 1, and the protein does not generate excessive immunological rejection; secondly, the protein can inhibit the expression of surface molecules of antigen presenting cells and inhibit the occurrence of acquired immune response; the protein inhibits host antigen presentation through multiple factors and multiple ways, and inhibits acquired immunity.

This invention discloses an enzyme- and pH-responsive nucleic acid loading and delivery material and its preparation method. The material can be used for efficient loading and delivery of nucleic acid molecules. The preparation method uses amphiphilic zwitterionic monomers to improve the reverse emulsion polymerization system, enhancing polymerization at the two-phase interface and avoiding the extrusion effect of polymerization in the aqueous core on nucleic acid molecules, thereby improving the loading efficiency of nucleic acid molecules. Further preparation of cross-linking agents MP-CL and CB-CL, which can cleave in response to matrix metalloproteinase II or cathepsin B, endows the nanogel with the ability to respond to charge reversal in the tumor matrix and to release nucleic acid molecules from tumor cells. The acid-sensitive blocks on the amphiphilic monomers give the nanogel lysosomal escape capability. The delivery material can efficiently deliver nucleic acid molecules into cells and exhibits excellent stability and biosafety.

The invention discloses DUSP23 targeted siRNA and application thereof, and belongs to the technical field of molecular biotechnology and genetic engineering. By researching the expression level of DUSP23 in liver cancer tissues, an action target of the DUSP23 gene is provided for treatment of liver cancer; the invention provides siRNA for inhibiting expression of a human DUSP23 gene and protein and application of the siRNA. The nucleotide sequence of the siRNA is shown as SEQ ID NO.5-SEQ ID NO.6. The invention further provides a preparation method of the siRNA. By transfecting the siRNA in a hepatoma carcinoma cell line, DUSP23 gene and protein expression can be regulated and interfered, cell proliferation and migration ability can be inhibited, cell cycle G0 / G1 phase arrest and cell apoptosis can be induced, and the siRNA has remarkable tumor inhibition activity on transplanted tumor in nude mice of hepatoma carcinoma cells.

The invention discloses a fish scale collagen skincare composition, a fish scale collagen cosmetic and a preparation method of the fish scale collagen skincare composition and the fish scale collagen cosmetic. The fish scale collagen skincare composition comprises 0.05-0.5 part of fish scale collagen, 0.05-0.5 part of madecassoside and 0.5-3 parts of a purslane extract. According to the invention, the fish scale collagen, madecassoside and purslane extract are combined to repair the skin barrier, calm and relieve nerves, relieve skin inflammatory response and improve sensitive skin in multiple aspects from the aspects of sensitive skin characteristics, possible mechanisms and the like instead of treating head pain and foot pain. The fish scale collagen, madecassoside and purslane extract are derived from fish scales, centella asiatica and purslane of perches respectively, are gifts given to human beings by the nature, are green and healthy, and can endow the perches with high economic value, and through the simple synergistic effect of the three components and the extremely small component addition amount, the basic state of the skin of sensitive skin is consolidated, and the skin care effect is improved. The symptoms of itching, redness and the like after the sensitive skin is stimulated are relieved.

The invention discloses trichina cathepsin B as well as a coding gene and application thereof, and belongs to the technical field of gene engineering. According to the invention, a food-grade L.lactis expression system is utilized to construct a lactic acid bacteria expression system of a TsCB gene, after the L.lactis recombinant strain pNZ8149-TsCB / L.lactis NZ3900 is subjected to intragastric administration on a mouse, the body can be induced to generate 2-type immune response, the recruitment of M2-type macrophages is increased, the infiltration of neutrophil is reduced, and the expression of proinflammatory factors and inflammatory mediators is inhibited, so that the colitis of the DSS mouse is improved; and a foundation is laid for subsequent research and development of food-grade oral insect-derived molecular medicines for treating colitis.

The invention discloses an injectable hydrogel pharmaceutical composition for an articular cavity as well as a preparation method and application of the injectable hydrogel pharmaceutical composition. The hydrogel pharmaceutical composition comprises gel particles and a medicine loaded in the gel particles, the gel particles are formed by cross-linking hyaluronic acid or salt thereof and silk fibroin through a cross-linking agent; the medicine comprises an anti-inflammatory drug and / or a growth factor. The preparation method is simple, good in safety and beneficial to industrial production. The uniform porous structure of the hydrogel is beneficial to adhesion and growth of bone cells, meanwhile, the double-load hydrogel loaded with the anti-inflammatory drug and the growth factor has good viscoelasticity and injectability and has the effects of synergistically resisting inflammation and promoting cartilage repair, and bone joint related diseases are treated in a bone joint intracavity injection mode; the drug residence time can be prolonged, and the bioavailability is improved.